Time to treatment and cost of thrombolysis

A multicenter comparison of tPA and rPA

Ali Seyedroudbari, E. Richard Kessler, Aryan N. Mooss, Richard L. Wurdeman, Mohan Bala, Daniel E. Hilleman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Study Objective: This study reports a comparison of the time to treatment and cost of administration of alteplase (tPA) and reteplase (rPA) in patients with acute myocardial infarction (MI). Design: Retrospective chart review. Setting: Hospital emergency department. Interventions: A retrospective chart review of 500 MI patients who received alteplase or reteplase was performed. A comparison of time from presentation in the emergency department to start of treatment was performed, and the cost of administration of drugs, including cost of supplies, monitoring time, and IV line complications, was calculated for each drug. Results: The time from presentation to start of treatment was significantly shorter for reteplase than alteplase (51 vs 34 min). This difference resulted from a shorter decision to treat to start of treatment time for reteplase (11 min) compared to alteplase (31 min). The cost of administration of alteplase ranged from $136 to $184 per patient, while the cost of administration of reteplase ranged from $87 to $120 per patient. Discussion: Given the similar safety and efficacy profiles of these thrombolytic agents, the advantages of reteplase in speed of administration and the reduction in cost should be considered when making formulary and drug product selection decisions.

Original languageEnglish
Pages (from-to)303-308
Number of pages6
JournalJournal of Thrombosis and Thrombolysis
Volume9
Issue number3
StatePublished - 2000

Fingerprint

Health Care Costs
Tissue Plasminogen Activator
Costs and Cost Analysis
Hospital Emergency Service
Myocardial Infarction
Formularies
Drug Costs
Fibrinolytic Agents
Hospital Departments
Pharmaceutical Preparations
reteplase
Therapeutics
Safety

All Science Journal Classification (ASJC) codes

  • Hematology
  • Cardiology and Cardiovascular Medicine

Cite this

Time to treatment and cost of thrombolysis : A multicenter comparison of tPA and rPA. / Seyedroudbari, Ali; Kessler, E. Richard; Mooss, Aryan N.; Wurdeman, Richard L.; Bala, Mohan; Hilleman, Daniel E.

In: Journal of Thrombosis and Thrombolysis, Vol. 9, No. 3, 2000, p. 303-308.

Research output: Contribution to journalArticle

Seyedroudbari, Ali ; Kessler, E. Richard ; Mooss, Aryan N. ; Wurdeman, Richard L. ; Bala, Mohan ; Hilleman, Daniel E. / Time to treatment and cost of thrombolysis : A multicenter comparison of tPA and rPA. In: Journal of Thrombosis and Thrombolysis. 2000 ; Vol. 9, No. 3. pp. 303-308.
@article{1cc103ac24204eedba8f8a715f815920,
title = "Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA",
abstract = "Study Objective: This study reports a comparison of the time to treatment and cost of administration of alteplase (tPA) and reteplase (rPA) in patients with acute myocardial infarction (MI). Design: Retrospective chart review. Setting: Hospital emergency department. Interventions: A retrospective chart review of 500 MI patients who received alteplase or reteplase was performed. A comparison of time from presentation in the emergency department to start of treatment was performed, and the cost of administration of drugs, including cost of supplies, monitoring time, and IV line complications, was calculated for each drug. Results: The time from presentation to start of treatment was significantly shorter for reteplase than alteplase (51 vs 34 min). This difference resulted from a shorter decision to treat to start of treatment time for reteplase (11 min) compared to alteplase (31 min). The cost of administration of alteplase ranged from $136 to $184 per patient, while the cost of administration of reteplase ranged from $87 to $120 per patient. Discussion: Given the similar safety and efficacy profiles of these thrombolytic agents, the advantages of reteplase in speed of administration and the reduction in cost should be considered when making formulary and drug product selection decisions.",
author = "Ali Seyedroudbari and Kessler, {E. Richard} and Mooss, {Aryan N.} and Wurdeman, {Richard L.} and Mohan Bala and Hilleman, {Daniel E.}",
year = "2000",
language = "English",
volume = "9",
pages = "303--308",
journal = "Journal of Thrombosis and Thrombolysis",
issn = "0929-5305",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Time to treatment and cost of thrombolysis

T2 - A multicenter comparison of tPA and rPA

AU - Seyedroudbari, Ali

AU - Kessler, E. Richard

AU - Mooss, Aryan N.

AU - Wurdeman, Richard L.

AU - Bala, Mohan

AU - Hilleman, Daniel E.

PY - 2000

Y1 - 2000

N2 - Study Objective: This study reports a comparison of the time to treatment and cost of administration of alteplase (tPA) and reteplase (rPA) in patients with acute myocardial infarction (MI). Design: Retrospective chart review. Setting: Hospital emergency department. Interventions: A retrospective chart review of 500 MI patients who received alteplase or reteplase was performed. A comparison of time from presentation in the emergency department to start of treatment was performed, and the cost of administration of drugs, including cost of supplies, monitoring time, and IV line complications, was calculated for each drug. Results: The time from presentation to start of treatment was significantly shorter for reteplase than alteplase (51 vs 34 min). This difference resulted from a shorter decision to treat to start of treatment time for reteplase (11 min) compared to alteplase (31 min). The cost of administration of alteplase ranged from $136 to $184 per patient, while the cost of administration of reteplase ranged from $87 to $120 per patient. Discussion: Given the similar safety and efficacy profiles of these thrombolytic agents, the advantages of reteplase in speed of administration and the reduction in cost should be considered when making formulary and drug product selection decisions.

AB - Study Objective: This study reports a comparison of the time to treatment and cost of administration of alteplase (tPA) and reteplase (rPA) in patients with acute myocardial infarction (MI). Design: Retrospective chart review. Setting: Hospital emergency department. Interventions: A retrospective chart review of 500 MI patients who received alteplase or reteplase was performed. A comparison of time from presentation in the emergency department to start of treatment was performed, and the cost of administration of drugs, including cost of supplies, monitoring time, and IV line complications, was calculated for each drug. Results: The time from presentation to start of treatment was significantly shorter for reteplase than alteplase (51 vs 34 min). This difference resulted from a shorter decision to treat to start of treatment time for reteplase (11 min) compared to alteplase (31 min). The cost of administration of alteplase ranged from $136 to $184 per patient, while the cost of administration of reteplase ranged from $87 to $120 per patient. Discussion: Given the similar safety and efficacy profiles of these thrombolytic agents, the advantages of reteplase in speed of administration and the reduction in cost should be considered when making formulary and drug product selection decisions.

UR - http://www.scopus.com/inward/record.url?scp=0034072763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034072763&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 303

EP - 308

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

SN - 0929-5305

IS - 3

ER -